SfN 2024: Where neuroscience meets community, collaboration, and innovation

At SfN 2024, neuroscientists converge to share groundbreaking research, fostering interdisciplinary connections and advancing the understanding of the brain.

Unveiling the role of SOS genes in E. coli survival during antibiotic treatment

When E. coli detects damage to its genetic material, it sends out an SOS signal that alters activity inside the cells.

June 20, 2024

Filament Health Completes the First Export of Botanical Psilocybin to Australia | Psychedelic Invest

Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, today announced that it

January 17, 2024

Bright Minds Announces Proposed Share Consolidation | Psychedelic Invest

Bright Minds Biosciences Inc. (CSE: DRUG / NASDAQ: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy,

June 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.